Thursday, July 14, 2022
HomeStartup Aulos Bioscience presents poster on Section 1/2 scientific trial of computationally...

[Biolojic in StreetInsider] Aulos Bioscience presents poster on Section 1/2 scientific trial of computationally designed IL-2 antibody AU-007 at 2022 ASCO annual assembly


LARKSPUR, Calif.–(BUSINESS WIRE)– Aulos Bioscience, an immuno-oncology firm working to revolutionize most cancers care via the event of probably best-in-class IL-2 therapeutics, at this time shared a Trials in Progress poster that’s being offered on the American Society of Medical Oncology (ASCO) 2022 Annual Assembly. The poster showcases the research design for the corporate’s first-in-human Section 1/2 trial of AU-007 that’s presently enrolling sufferers in Australia. AU-007 is a human monoclonal antibody computationally designed by Biolojic Design, with a extremely differentiated method to harnessing the facility of interleukin-2 (IL-2) to eradicate stable tumors.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments